Video

Dr. Paz-Ares Discusses Pemetrexed Clinical Trial

Author(s):

Luis Paz-Ares, MD, PhD

Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial

Luis Paz-Ares, MD, PhD, chair of Oncology at Seville University Hospital in Spain, discusses the pemetrexed advanced nonsquamous non—small cell lung cancer clinical trial.

Related Videos
Yungan Tao, MD
Jared Weiss, MD
Guru P. Sonpavde, MD
Martin H. Voss, MD
Sally Lau, MD
Hope S. Rugo, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Srikala Sridhar, MD, MSc, FRCPC
Related Content
Lung Cancer - stock.adobe.com
October 14th 2024

Sunvozertinib Receives Breakthrough Therapy Designation for Treatment-Naive EGFR Exon 20+ NSCLC in China

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
October 7th 2024

Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD

Josh Riggs, of Oncocyte
October 13th 2024

Assay Predicts Response to Neoadjuvant Atezolizumab Plus Chemotherapy in TNBC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Sunvozertinib in EGFR exon 20–positive NSCLC Sunvozertinib in EGFR exon 20–positive NSCLC | Image Credit: © blueringmedia - stock.adobe.com
October 11th 2024

NMPA Grants Marketing Approval to NGS-Based Companion Diagnostic for Sunvozertinib in EGFR Exon 20+ NSCLC

Eric Kumar Singhi, MD, of MD Anderson Cancer Center
October 9th 2024

Exploring Facets of Both the SCLC and NSCLC Therapeutic Landscapes